text:
Department of Health and Human Services
Participating Organizations
National Institutes of Health (NIH), (http://www.nih.gov)
Components of Participating Organizations
National Institute of Child Health and Human Development (NICHD/NIH), (http://www.nichd.nih.gov)
National Institute on Deafness and Other Communication Disorders (NIDCD/NIH), (http://www.nidcd.nih.gov)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH), (http://www.niddk.nih.gov)
Title: Innovative Therapies and Clinical Studies for Screenable Disorders (R03)
Announcement Type
Update: The following update relating to this announcement has been issued:
Program Announcement (PA) Number: PAR-06-061
Catalog of Federal Domestic Assistance Number(s)
93.865, 93.847, 93.173
Key Dates
Release Date: November 7, 2005
Letters of Intent Receipt Date(s): 30 days prior to the application receipt date
Application Submission Dates(s): Standard dates apply, please see https://grants.nih.gov/grants/funding/submissionschedule.htm for details
AIDS Application Receipt Dates(s): Not applicable
Peer Review Date(s): Standard dates apply, please see https://grants.nih.gov/grants/funding/submissionschedule.htm for details
Council Review Date(s): Standard dates apply, please see https://grants.nih.gov/grants/funding/submissionschedule.htm for details
Earliest Anticipated Start Date: Standard dates apply, please see https://grants.nih.gov/grants/funding/submissionschedule.htm for details
Additional Information To Be Available Date (Url Activation Date): Not Applicable
EXPIRATION DATE for R03 Non-AIDS Applications: March 2, 2006
EXPIRATION DATE for R03 AIDS and AIDS-Related Applications: May 2, 2006
Due Dates for E.O. 12372
Not Applicable
Additional Overview Content
Executive Summary
Part I Overview Information
Part II Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
Section II. Award Information
1. Mechanism(s) of Support
2. Funds Available
Section III. Eligibility Information
1. Eligible Applicants
A. Eligible Institutions
B. Eligible Individuals
2.Cost Sharing or Matching
3. Other - Special Eligibility Criteria
Section IV. Application and Submission Information
1. Address to Request Application Information
2. Content and Form of Application Submission
3. Submission Dates and Times
A. Submission and Review and Anticipated Start Dates
1. Letter of Intent
B. Sending an Application to the NIH
C. Application Processing
4. Intergovernmental Review
5. Funding Restrictions
6. Other Submission Requirements
Section V. Application Review Information
1. Criteria
2. Review and Selection Process
A. Additional Review Criteria
B. Additional Review Considerations
C. Sharing Research Data
D. Sharing Research Resources
3. Anticipated Announcement and Award Dates
Section VI. Award Administration Information
1. Award Notices
2. Administrative and National Policy Requirements
3. Reporting
Section VII. Agency Contact(s)
1. Scientific/Research Contact(s)
2. Peer Review Contact(s)
3. Financial/ Grants Management Contact(s)
Section VIII. Other Information - Required Federal Citations
1. Research Objectives
The purpose of this announcement is to stimulate translational research on potential therapeutic interventions for currently screened conditions and "high priority" genetic conditions for which screening could be possible in the near future. Special emphasis is placed on research relating to some of the "high priority" conditions identified in the report, "Newborn Screening: Toward a Uniform Screening Panel and System," which the Maternal and Child Health Bureau sponsored and the American College of Medical Genetics (http://mchb.hrsa.gov/screening) developed. In this PAR, a "high priority" condition is a condition for which the development of an efficacious therapy would make the condition amenable to newborn screening. Research designed to understand the natural history of these conditions will facilitate the identification of potential therapeutic targets, with an ultimate goal of developing more targeted and effective therapies.
As a public health genetic screening program, newborn screening's main aim is the early detection and treatment of pre-symptomatic infants. This 40-year public health program has evolved from screening for a single condition, phenylketonuria, to encompassing more than 30 different conditions. The early detection of genetic conditions in newborn infants allows extra time for therapy that can have a dramatic impact on the clinical severity of the condition in the affected child. If left undiagnosed and untreated, these conditions can cause irreversible mental retardation, physical disability, neurological damage and even death.
Advancements in our knowledge of the genetic and molecular bases of various conditions, as well as technological developments (i.e., tandem mass spectrometry), have paved the way for the expansion of newborn screening. Yet, there have not been corresponding improvements and development of treatments for these screenable conditions.
Furthermore, though screening programs test more than 4.1 million newborn infants and diagnose 5,000 with a genetic condition annually, these programs miss more than 1,000 affected newborn infants due to the lack of uniform newborn screening across the United States. In response to these data, experts recommended that all newborns in the United States be screened for a set of 29 conditions, regardless of the State in which they were born. The American College of Medical Genetics developed these recommendations and published them in a Maternal and Child Health Bureau report entitled "Newborn Screening: Toward a Uniform Screening Panel and System" (http://mchb.hrsa.gov/screening). The Secretary's Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children endorsed the recommendations.
Since the availability of an effective treatment is often a criterion for inclusion of a condition on a newborn screening panel, the intent of this PAR is to support research and development of therapies for those conditions that currently do not meet this criterion. The purpose of supporting the development of effective therapeutic interventions to expand newborn screening is to improve the health outcomes of infants having or at risk for heritable disorders.
Research Scope
Applications submitted in response to this PAR should focus on topic(s) related to the understanding and/or development of therapeutic interventions for currently screened conditions and "high priority" genetic conditions for which investigators could potentially develop screening tests in the near future (for instance, cystic fibrosis, severe combined immunodeficiency, Duchenne muscular dystrophy. spinal muscular atrophy, lysosomal storage diseases - Pompe disease, Fabry disease, the mucopolysaccharidoses and Krabbe disease).
The NIDCD is particularly interested in receiving applications related to screening and therapies for genetic causes of hearing loss as well as hearing loss due to infectious agents, specifically congenital Cytomegalovirus (CMV).
The participating institutes invite investigators with diverse scientific interests to apply their expertise in basic, translational or clinical research to develop innovative and novel approaches for studying and treating these conditions. Applicants are strongly encouraged to contact program staff prior to submitting a proposal that includes a clinical trial or interventional study in humans.
Possible areas of investigation include, but are not limited to:
Interventions may be intended to be used as a single treatment agent, as an adjuvant to existing therapies or as a combination therapy of known agents. The specific aims of the project must be clearly and concisely presented. These should include a clear specification of the validated primary and major secondary endpoints to be measured with a clear differentiation of the importance of various endpoints.
See Section VIII, Other Information - Required Federal Citations, for policies related to this announcement.Section II. Award Information
1. Mechanism(s) of Support
This funding opportunity will use the NIH Small Grant (R03) award mechanism(s). As an applicant, you will be solely responsible for planning, directing, and executing the proposed project.
The small grant (R03) mechanism provides support of pilot and/or feasibility studies for concepts that are sound and justifiable, but not sufficiently developed for the R01 mechanism.
Applicants for the NIH Small Grant (R03) should follow the guidelines published in the NIH Guide for Grants and Contracts at https://grants.nih.gov/grants/guide/pa-files/PA-03-108.html.
This funding opportunity uses just-in-time concepts. It also uses the modular budget format described in the PHS 398 application instructions (see https://grants.nih.gov/grants/funding/modular/modular.htm).
This funding opportunity will utilize the R03 mechanism, but will be run in parallel with two other program announcements of identical scientific scope, PAR-06-060 that will utilize the traditional research project grant (R01) mechanism, and PAR-06-059 that will utilize the exploratory/developmental (R21) grant mechanism.
2. Funds Available
Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Although the financial plans of the ICs provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications.
The R03 mechanism allows for a project period of up to 2 years and budget request of up to $50,000 total direct costs per year.
Facilities and administrative costs requested by consortium participants are not included in the direct cost limitation see NOT-OD-05-004.
1. Eligible Applicants
1.A. Eligible Institutions
You may submit (an) application(s) if your organization has any of the following characteristics:
An application may include one or more institutions (e.g., individual institutions, consortia, centers) with established clinical, laboratory, and statistical resources.
1.B. Eligible Individuals
Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs.
2. Cost Sharing or Matching
Cost sharing is not required.
The most current Grants Policy Statement can be found at: https://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm#matching_or_cost_sharing
3. Other-Special Eligibility Criteria
Not applicable
1. Address to Request Application Information
The PHS 398 application instructions are available at https://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. Applicants must use the currently approved version of the PHS 398. For further assistance contact GrantsInfo, Telephone (301) 710-0267, Email: firstname.lastname@example.com.
Telecommunications for the hearing impaired: TTY 301-451-5936.
2. Content and Form of Application Submission
Applications must be prepared using the most current PHS 398 research grant application instructions and forms. Applications must have a D&B Data Universal Numbering System (DUNS) number as the universal identifier when applying for Federal grants or cooperative agreements. The D&B number can be obtained by calling (866) 705-5711 or through the web site at http://www.dnb.com/us/. The D&B number should be entered on line 11 of the face page of the PHS 398 form.
The title and number of this funding opportunity must be typed on line 2 of the face page of the application form and the YES box must be checked.
Foreign Organizations
Several special provisions apply to applications submitted by foreign organizations:
3.A. Submission, Review and Anticipated Start Dates
Letter of Intent Submission Date: 30 days prior to the application receipt date
Application Submission Date(s): Standard dates apply, please see https://grants.nih.gov/grants/funding/submissionschedule.htm for details
Peer Review Date: Standard dates apply, please see https://grants.nih.gov/grants/funding/submissionschedule.htm for details
Council Review Date: Standard dates apply, please see https://grants.nih.gov/grants/funding/submissionschedule.htm for details
Earliest Anticipated Start Date: Standard dates apply, please see https://grants.nih.gov/grants/funding/submissionschedule.htm for details
3.A.1. Letter of Intent
Prospective applicants are asked to submit a letter of intent that includes the following information:
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
The letter of intent is to be sent by the date listed at the beginning of this document.
The letter of intent should be sent to:
Gilian Engelson, MPH
Mental Retardation and Developmental Disabilities Branch
Center for Developmental Biology and Perinatal Medicine
National Institute of Child Health and Human Development
6100 Executive Boulevard, Room 4A05E, MSC 7510
Bethesda, MD 20892-7510
(Rockville, MD 20852 for courier or express service)
Telephone: (301) 451-2137
Email: firstname.lastname@example.com
3.B. Sending an Application to the NIH
Applications must be prepared using the research grant application forms found in the PHS 398 instructions for preparing a research grant application. Submit a signed, typewritten original of the application, including the checklist, and five signed photocopies in one package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710 (U.S. Postal Service Express or regular mail)
Bethesda, MD 20817 (for express/courier service; non-USPS service)
Personal deliveries of applications are no longer permitted (see https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-040.html).
3.C. Application Processing
Applications must be submitted on or before the application submission date(s) described above (Section IV.3.A.). If an application is received after that date, it will be returned to the applicant without review.
Upon receipt applications will be evaluated for completeness by CSR. Incomplete applications will not be reviewed.
The NIH will not accept any application in response to this funding opportunity that is essentially the same as one currently pending initial merit review unless the applicant withdraws the pending application. The NIH will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of a substantial revision of an application already reviewed, but such application must include an Introduction addressing the previous critique.
Although there is no immediate acknowledgement of the receipt of an application, applicants are generally notified of the review and funding assignment within eight (8) weeks.
4. Intergovernmental Review
This initiative is not subject to intergovernmental review.
5. Funding Restrictions
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement. The Grants Policy Statement can be found at https://grants.nih.gov/grants/policy/policy.htm.
Pre-Award Costs are allowable. A grantee may, at its own risk and without NIH prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new or competing continuation award if such costs: are necessary to conduct the project, and would be allowable under the grant, if awarded, without NIH prior approval. If specific expenditures would otherwise require prior approval, the grantee must obtain NIH approval before incurring the cost. NIH prior approval is required for any costs to be incurred more than 90 days before the beginning date of the initial budget period of a new or competing continuation award.
The incurrence of pre-award costs in anticipation of a competing or non-competing award imposes no obligation on NIH either to make the award or to increase the amount of the approved budget if an award is made for less than the amount anticipated and is inadequate to cover the pre-award costs incurred. NIH expects the grantee to be fully aware that pre-award costs result in borrowing against future support and that such borrowing must not impair the grantee's ability to accomplish the project objectives in the approved time frame or in any way adversely affect the conduct of the project. See NIH Grants Policy Statement https://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm.
6. Other Submission Requirements
Specific Instructions for Modular Grant Applications
Applications requesting up to $250,000 per year in direct costs must be submitted in a modular budget format. The modular budget format simplifies the preparation of the budget in these applications by limiting the level of budgetary detail. Applicants request direct costs in $25,000 modules. Section C of the research grant application instructions for the PHS 398 at https://grants.nih.gov/grants/funding/phs398/phs398.html includes step-by-step guidance for preparing modular budgets. Applicants must use the currently approved version of the PHS 398. Additional information on modular budgets is available at https://grants.nih.gov/grants/funding/modular/modular.htm.
Plan for Sharing Research Data
The precise content of the data-sharing plan will vary, depending on the data being collected and how the investigator is planning to share the data. Applicants who are planning to share data may wish to describe briefly the expected schedule for data sharing, the format of the final dataset, the documentation to be provided, whether or not any analytic tools also will be provided, whether or not a data-sharing agreement will be required and, if so, a brief description of such an agreement (including the criteria for deciding who can receive the data and whether or not any conditions will be placed on their use), and the mode of data sharing (e.g., under their own auspices by mailing a disk or posting data on their institutional or personal website, through a data archive or enclave). Investigators choosing to share under their own auspices may wish to enter into a data-sharing agreement. References to data sharing may also be appropriate in other sections of the application.
All applicants must include a plan for sharing research data in their application. The data sharing policy is available at https://grants.nih.gov/grants/policy/data_sharing. All investigators responding to this funding opportunity should include a description of how final research data will be shared, or explain why data sharing is not possible.
The reasonableness of the data sharing plan or the rationale for not sharing research data will be assessed by the reviewers. However, reviewers will not factor the proposed data sharing plan into the determination of scientific merit or the priority score.
Sharing Research Resources
NIH policy requires that grant awardee recipients make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication (NIH Grants Policy Statement https://grants.nih.gov/archive/archive/grants/policy/nihgps_2003/index.htm and https://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm#_Toc54600131). Investigators responding to this funding opportunity should include a plan for sharing research resources addressing how unique research resources will be shared or explain why sharing is not possible.
The adequacy of the resources sharing plan and any related data sharing plans will be considered by Program staff of the funding organization when making recommendations about funding applications. The effectiveness of the resource sharing will be evaluated as part of the administrative review of each non-competing Grant Progress Report (PHS 2590, https://grants.nih.gov/grants/funding/2590/2590.htm). See Section VI.3. Reporting.
The sharing of biomaterials, data, and software in a timely manner has been an essential element in the rapid progress that has been made in the genetic and molecular analysis of human diseases. All applicants who respond to this PAR must propose plans for sharing data and biomaterials generated through the grant. Applicants should explain how funds for the storage and distribution of data and biomaterials will be obtained, and may request such funds in the budget of the application. It is expected that the information to be shared will include clinical, diagnostic, and pedigree structure information. Biomaterials to be shared should include patient DNAs and cell lines, mouse or other animal models and other resources and reagents generated through the grant. When possible, data and biomaterials should be placed in databases or repositories that will permit their efficient distribution to investigators throughout the scientific community (for example, the NIMH Human Genetics Initiative for autism data and biomaterials; see http://nimhgenetics.org). Rapid sharing of data and biomaterials is strongly encouraged by the NIH.
The investigator's data and resource sharing plan should, when applicable, specify the following elements: (1) the creation of comprehensive and verified databases that contain all clinical, diagnostic, and genetic information collected and produced in the project; (2) if possible, the establishment of high-quality cell lines, from which DNA will be extracted and stored, for all subjects studied from whom blood or other biological samples have been obtained; (3) mechanisms by which all databases and any biomaterials (DNA samples, cell lines, mouse or other animal models, reagents) are widely distributed to qualified investigators in the scientific community; (4) a protocol for wide dissemination of these data and biomaterials; and (5) a timetable for distribution.
The Scientific Review Group will evaluate the proposed sharing plan and comment on its adequacy in an administrative note in the Summary Statement. Reviewers will not factor the proposed data-sharing plan into the determination of scientific merit or priority score. The adequacy of the plan will be considered by NIH staff in determining whether the grant shall be awarded. The sharing plan as approved, after negotiation with the applicant when necessary, will be a condition of the awardSection V. Application Review Information
1. Criteria
Only the review criteria described below will be considered in the review process.
2. Review and Selection Process
Applications submitted for this funding opportunity will be assigned to the ICs on the basis of established PHS referral guidelines.
Applications that are complete will be evaluated for scientific and technical merit by an appropriate review group convened by National Institute of Child Health and Human Development in accordance with the review criteria stated below.
As part of the initial merit review, all applications will:
The following will be considered in making funding decisions:
The goals of NIH supported research are to advance our understanding of biological systems, to improve the control of disease, and to enhance health. In their written critiques, reviewers will be asked to comment on each of the following criteria in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered in assigning the overall score, weighting them as appropriate for each application. Note that an application does not need to be strong in all categories to be judged likely to have major scientific impact and thus deserve a high priority score. For example, an investigator may propose to carry out important work that by its nature is not innovative but is essential to move a field forward.
Significance: Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge or clinical practice be advanced? What will be the effect of these studies on the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Approach: Are the conceptual or clinical framework, design, methods, and analyses adequately developed, well integrated, well reasoned, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics?
Innovation: Is the project original and innovative? For example: Does the project challenge existing paradigms or clinical practice; address an innovative hypothesis or critical barrier to progress in the field? Does the project develop or employ novel concepts, approaches, methodologies, tools, or technologies for this area?
Investigators: Are the investigators appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers? Does the investigative team bring complementary and integrated expertise to the project (if applicable)?
Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed studies benefit from unique features of the scientific environment, or subject populations, or employ useful collaborative arrangements? Is there evidence of institutional support?
2.A. Additional Review Criteria:
In addition to the above criteria, the following items will continue to be considered in the determination of scientific merit and the priority score:
Protection of Human Subjects from Research Risk: The involvement of human subjects and protections from research risk relating to their participation in the proposed research will be assessed (see the Research Plan, Section E on Human Subjects in the PHS Form 398).
Inclusion of Women, Minorities and Children in Research: The adequacy of plans to include subjects from both genders, all racial and ethnic groups (and subgroups), and children as appropriate for the scientific goals of the research will be assessed. Plans for the recruitment and retention of subjects will also be evaluated (see the Research Plan, Section E on Human Subjects in the PHS Form 398).
Care and Use of Vertebrate Animals in Research: If vertebrate animals are to be used in the project, the five items described under Section F of the PHS Form 398 research grant application instructions will be assessed.
Biohazards: If materials or procedures are proposed that are potentially hazardous to research personnel and/or the environment, determine if the proposed protection is adequate.
2.B. Additional Review Considerations
Budget: The reasonableness of the proposed budget and the requested period of support in relation to the proposed research. The priority score should not be affected by the evaluation of the budget.
2.C. Sharing Research Data
Data Sharing Plan: The reasonableness of the data sharing plan or the rationale for not sharing research data will be assessed by the reviewers. However, reviewers will not factor the proposed data sharing plan into the determination of scientific merit or the priority score. The presence of a data sharing plan will be part of the terms and conditions of the award. The funding organization will be responsible for monitoring the data sharing policy.
2.D. Sharing Research Resources
NIH policy requires that grant awardee recipients make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication (See the NIH Grants Policy Statement https://grants.nih.gov/archive/grants/policy/nihgps/part_ii_5.htm#availofrr and http://www.ott.nih.gov/policy/rt_guide_final.html). Investigators responding to this funding opportunity should include a sharing research resources plan addressing how unique research resources will be shared or explain why sharing is not possible.
The reviewers will be asked to assess the adequacy of the investigator's data and resource sharing plan with respect to the following elements when appropriate: (1) the creation of comprehensive and verified databases that contain all clinical, diagnostic, and genetic information collected and produced in the project; (2) if possible, the establishment of high-quality cell lines, from which DNA will be extracted and stored, for all subjects studied from whom blood or other biological samples have been obtained; (3) mechanisms by which all databases and any biomaterials (DNA samples, cell lines, mouse or other animal models, reagents) are widely distributed to qualified investigators in the scientific community; (4) a protocol for wide dissemination of these data and biomaterials; and (5) a timetable for distribution. The Initial Review Group will evaluate the proposed sharing plan and comment on its adequacy in an administrative note in the Summary Statement. Reviewers will not factor the proposed data-sharing plan into the determination of scientific merit or priority score.
The adequacy of the resources sharing plan will be considered by Program staff of the funding organization when making recommendations about funding applications. Program staff may negotiate modifications of the data and resource sharing plans with the awardee before recommending funding of an application. The final version of the data and resource sharing plans negotiated by both will become a condition of the award of the grant. The effectiveness of the resource sharing will be evaluated as part of the administrative review of each non-competing Grant Progress Report (PHS 2590). See Section VI.3. Reporting.
3. Anticipated Announcement and Award Dates
Not applicable
1. Award Notices
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant. For details, applicants may refer to the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General (https://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm).
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization. The NoA signed by the grants management officer is the authorizing document. Once all administrative and programmatic issues have been resolved, the NoA will be generated via email notification from the awarding component to the grantee business official (designated in item 14 on the Application Face Page). If a grantee is not email enabled, a hard copy of the NoA will be mailed to the business official.
Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs. See Also Section IV.5. Funding Restrictions.
2. Administrative and National Policy Requirements
The terms and conditions of the award may include specific requirements for data and/or resource sharing including depositing cell lines, DNA samples, biomaterials or other mouse and animal models into National repositories.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the notice of award. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General (https://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm) and Part II Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities (https://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm).
3. Reporting
Awardees will be required to submit the PHS Non-Competing Grant Progress Report, Form 2590 annually (https://grants.nih.gov/grants/funding/2590/2590.htm) and financial statements as required in the NIH Grants Policy Statement.
We encourage your inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants. Inquiries may fall into three areas: scientific/research, peer review, and financial or grants management issues:
1. Scientific/Research Contacts:
Gilian Engelson, MPH
Mental Retardation and Developmental Disabilities Branch
Center for Developmental Biology and Perinatal Medicine
National Institute of Child Health and Human Development
6100 Executive Boulevard, Room 4A05E, MSC 7510
Bethesda, MD 20892-7510 (For FedEx/UPS use Rockville, MD 20852)
Telephone: (301) 451-2137
Email: firstname.lastname@example.com
Catherine McKeon, Ph.D.
Senior Advisor for Genetic Research
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 6103, MSC 5460
Bethesda, MD 20892-5460 ( For FedEx/UPS use 20817)
Telephone: (301) 594-8810
Email: firstname.lastname@example.com
Bracie Watson, Jr., Ph.D.
Program Director, Hearing Program
Division of Extramural Research
National Institute on Deafness and Other Communication Disorders
6120 Executive Boulevard, 400-C, MSC-7180
Bethesda, MD 20892-7180
Telephone: (301) 402-3458
Email: firstname.lastname@example.com
2. Peer Review Contacts:
Robert H. Stretch, Ph.D.
Director, Division of Scientific Review
National Institute of Child Health and Human Development
6100 Executive Boulevard, Room 5B01, MSC 7510
Bethesda, MD 20892-7510 (For FEDEX/UPS use Rockville, MD 20852)
Telephone: (301) 496-1485
Email: email@example.com
3. Financial or Grants Management Contacts:
Christopher Robey
Grants Management Team Leader
National Institute of Child Health and Human Development
6100 Executive Boulevard, Room 8A17K, MSC 7510
Bethesda, Maryland 20892 (For Fed Ex/UPS use 20852)
Telephone: (301) 435-6996
Email: firstname.lastname@example.com
Christopher Myers
Grants Management Branch
Division of Extramural Activities
National Institute on Deafness and Other Communication Disorders
6120 Executive Boulevard, 400-B, MSC 7180
Bethesda, MD 20892-7180 (For Fed Ex/UPS use 20852)
Telephone: 301-435-0713
Email: email@example.com
Mary K. Rosenberg
Acting, Supervisory Grants Management Specialist
Senior Grants Management Specialist
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 745, MSC 5456
Bethesda, MD 20892 (express mail zip 20817)
Telephone: 301-594-8891
FAX: 301-480-3504 or 301-594-9523
Email: firstname.lastname@example.com
Required Federal Citations
Use of Animals in Research:
Recipients of PHS support for activities involving live, vertebrate animals must comply with PHS Policy on Humane Care and Use of Laboratory Animals (https://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf) as mandated by the Health Research Extension Act of 1985 (https://grants.nih.gov/grants/olaw/references/hrea1985.htm), and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm) as applicable.
Human Subjects Protection:
Federal regulations (45CFR46) require that applications and proposals involving human subjects must be evaluated with reference to the risks to the subjects, the adequacy of protection against these risks, the potential benefits of the research to the subjects and others, and the importance of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Data and Safety Monitoring Plan:
Data and safety monitoring is required for all types of clinical trials, including physiologic toxicity and dose-finding studies (phase I); efficacy studies (Phase II); efficacy, effectiveness and comparative trials (Phase III). Monitoring should be commensurate with risk. The establishment of data and safety monitoring boards (DSMBs) is required for multi-site clinical trials involving interventions that entail potential risks to the participants (NIH Policy for Data and Safety Monitoring, NIH Guide for Grants and Contracts, https://grants.nih.gov/grants/guide/notice-files/not98-084.html).
Sharing Research Data:
Investigators submitting an NIH application seeking $500,000 or more in direct costs in any single year are expected to include a plan for data sharing or state why this is not possible (https://grants.nih.gov/grants/policy/data_sharing).
Investigators should seek guidance from their institutions, on issues related to institutional policies and local IRB rules, as well as local, State and Federal laws and regulations, including the Privacy Rule. Reviewers will consider the data sharing plan but will not factor the plan into the determination of the scientific merit or the priority score.
Access to Research Data through the Freedom of Information Act:
The Office of Management and Budget (OMB) Circular A-110 has been revised to provide access to research data through the Freedom of Information Act (FOIA) under some circumstances. Data that are (1) first produced in a project that is supported in whole or in part with Federal funds and (2) cited publicly and officially by a Federal agency in support of an action that has the force and effect of law (i.e., a regulation) may be accessed through FOIA. It is important for applicants to understand the basic scope of this amendment. NIH has provided guidance at https://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm. Applicants may wish to place data collected under this funding opportunity in a public archive, which can provide protections for the data and manage the distribution for an indefinite period of time. If so, the application should include a description of the archiving plan in the study design and include information about this in the budget justification section of the application. In addition, applicants should think about how to structure informed consent statements and other human subjects procedures given the potential for wider use of data collected under this award.
Sharing of Model Organisms:
NIH is committed to support efforts that encourage sharing of important research resources including the sharing of model organisms for biomedical research (see https://grants.nih.gov/grants/policy/model_organism/index.htm). At the same time the NIH recognizes the rights of grantees and contractors to elect and retain title to subject inventions developed with Federal funding pursuant to the Bayh Dole Act (see the NIH Grants Policy Statement https://grants.nih.gov/archive/archive/grants/policy/nihgps_2003/index.htm). All investigators submitting an NIH application or contract proposal, beginning with the October 1, 2004 receipt date, are expected to include in the application/proposal a description of a specific plan for sharing and distributing unique model organism research resources generated using NIH funding or state why such sharing is restricted or not possible. This will permit other researchers to benefit from the resources developed with public funding. The inclusion of a model organism sharing plan is not subject to a cost threshold in any year and is expected to be included in all applications where the development of model organisms is anticipated.
Inclusion of Women And Minorities in Clinical Research:
It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH-supported clinical research projects unless a clear and compelling justification is provided indicating that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing clinical research should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html); a complete copy of the updated Guidelines is available at https://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. The amended policy incorporates: the use of an NIH definition of clinical research; updated racial and ethnic categories in compliance with the new OMB standards; clarification of language governing NIH-defined Phase III clinical trials consistent with the new PHS Form 398; and updated roles and responsibilities of NIH staff and the extramural community. The policy continues to require for all NIH-defined Phase III clinical trials that: a) all applications or proposals and/or protocols must provide a description of plans to conduct analyses, as appropriate, to address differences by sex/gender and/or racial/ethnic groups, including subgroups if applicable; and b) investigators must report annual accrual and progress in conducting analyses, as appropriate, by sex/gender and/or racial/ethnic group differences.
Inclusion of Children as Participants in Clinical Research:
The NIH maintains a policy that children (i.e., individuals under the age of 21) must be included in all clinical research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them.
All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines" on the inclusion of children as participants in research involving human subjects (https://grants.nih.gov/grants/funding/children/children.htm).
Required Education on the Protection of Human Subject Participants:
NIH policy requires education on the protection of human subject participants for all investigators submitting NIH applications for research involving human subjects and individuals designated as key personnel. The policy is available at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
Human Embryonic Stem Cells (hESC):
Criteria for federal funding of research on hESCs can be found at http://stemcells.nih.gov/index.asp and at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Only research using hESC lines that are registered in the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding (http://escr.nih.gov). It is the responsibility of the applicant to provide in the project description and elsewhere in the application as appropriate, the official NIH identifier(s) for the hESC line(s)to be used in the proposed research. Applications that do not provide this information will be returned without review.
NIH Public Access Policy:
NIH-funded investigators are requested to submit to the NIH manuscript submission (NIHMS) system (http://www.nihms.nih.gov) at PubMed Central (PMC) an electronic version of the author's final manuscript upon acceptance for publication, resulting from research supported in whole or in part with direct costs from NIH. The author's final manuscript is defined as the final version accepted for journal publication, and includes all modifications from the publishing peer review process.
NIH is requesting that authors submit manuscripts resulting from 1) currently funded NIH research projects or 2) previously supported NIH research projects if they are accepted for publication on or after May 2, 2005. The NIH Public Access Policy applies to all research grant and career development award mechanisms, cooperative agreements, contracts, Institutional and Individual Ruth L. Kirschstein National Research Service Awards, as well as NIH intramural research studies. The Policy applies to peer-reviewed, original research publications that have been supported in whole or in part with direct costs from NIH, but it does not apply to book chapters, editorials, reviews, or conference proceedings. Publications resulting from non-NIH-supported research projects should not be submitted.
For more information about the Policy or the submission process please visit the NIH Public Access Policy Web site at http://www.nih.gov/about/publicaccess/ and view the Policy or other Resources and Tools including the Authors' Manual (http://www.nih.gov/about/publicaccess/publicaccess_Manual.htm).
Standards for Privacy of Individually Identifiable Health Information:
The Department of Health and Human Services (DHHS) issued final modification to the "Standards for Privacy of Individually Identifiable Health Information", the "Privacy Rule", on August 14, 2002 The Privacy Rule is a federal regulation under the Health Insurance Portability and Accountability Act (HIPAA) of 1996 that governs the protection of individually identifiable health information, and is administered and enforced by the DHHS Office for Civil Rights (OCR).
Decisions about applicability and implementation of the Privacy Rule reside with the researcher and his/her institution. The OCR website (http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including a complete Regulation Text and a set of decision tools on "Am I a covered entity?" Information on the impact of the HIPAA Privacy Rule on NIH processes involving the review, funding, and progress monitoring of grants, cooperative agreements, and research contracts can be found at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs in NIH Grant Applications or Appendices:
All applications and proposals for NIH funding must be self-contained within specified page limitations. Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) should not be used to provide information necessary to the review because reviewers are under no obligation to view the Internet sites. Furthermore, we caution reviewers that their anonymity may be compromised when they directly access an Internet site.
Healthy People 2010:
The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS-led national activity for setting priority areas. This PAR is related to one or more of the priority areas. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
Authority and Regulations:
This program is described in the Catalog of Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement. The NIH Grants Policy Statement can be found at https://grants.nih.gov/grants/policy/policy.htm.
The PHS strongly encourages all grant recipients to provide a smoke-free workplace and discourage the use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Loan Repayment Programs:
NIH encourages applications for educational loan repayment from qualified health professionals who have made a commitment to pursue a research career involving clinical, pediatric, contraception, infertility, and health disparities related areas. The LRP is an important component of NIH's efforts to recruit and retain the next generation of researchers by providing the means for developing a research career unfettered by the burden of student loan debt. Note that an NIH grant is not required for eligibility and concurrent career award and LRP applications are encouraged. The periods of career award and LRP award may overlap providing the LRP recipient with the required commitment of time and effort, as LRP awardees must commit at least 50% of their time (at least 20 hours per week based on a 40 hour week) for two years to the research. For further information, please see: http://www.lrp.nih.gov.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
Research (OER)
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.


text:
Read More
Invertebrates. This is a great range of animals. Remember that 95% of the animal species in the planet belong to this group. That is why I do not intend to fully expose the wide world of invertebrates (I'm no expert at this), but only to show those photos I have made over the years featuring some animals that fall into this category, mainly insects and spiders, and even some mollusks. I'm not specialized in macro or close-up photography, and in many of the pictures I just wanted to show these interesting creatures in their environment, looking as usual for aesthetic beauty in colors and compositions.

subset: commoncrawl


text:
When I was in university we did a group project which surveyed the factors people take into consideration when deciding on a cinema. Location, price, variety of movies, comfort of seats were among the common and quickly churned options.
Then I said 'popcorn'. And everyone looked at me like I just answered 'elephant' to what the smallest animal in the world is.
HAHAHA!! What!! I love my popcorn and how much I enjoy the movie is partially dependent on the quality of popcorn I put into my mouth. Some make it too sweet, some make too bland, some make it too crunchy, some are too lao hong.
I like my popcorn sweet most of the time, but not too sweet. Butter proportion is important too. I like the combination of Garrett Popcorn's Chicago Mix - a combination of caramel and cheesecorn, however the crunchiness and freshness disappear within half an hour. Such short-lived excellence. 🙁
The topic of discussion isn't popcorn though, we're talking about this fun-tasting lip exfoliating scrub from Lush. It's my first ever product from the brand too.
I was really excited when Lush first landed on our shores but when I came within 3 metres of the store at Wisma Atria, the pungent smell immediately consumed me. From then on I would walk the other side of the basement level just to avoid the overpowering smells (to me) or aromas (maybe to you) emitting from the store.
But then one day I had enough of my lips peeling so often that I researched on exfoliating lip scrubs and somehow saw reviews on Lush Lip Scrubs.
One thing led to another and I found myself holding my breath and walking into Lush. Holds breath: *hurrgh!* >.<"
The friendly store assistant smiled at me and asked "Are you Bun Bun?".
'Oh no, oh no, I have no makeup on and I'm dressed so shabbily', I thought. But I said "Yes".
"Oh! It's so nice to see you! I felt so angry for you when I read about your facial incident!! You should sue them!"
I just laughed and said "Thank you! Haha, I get that a lot, but it's complicated".
That was probably about 2 months ago, at the height of the legal phase brought about by the unfortunate facial incident.
Then she proceeded to introduce the Lush Lip Scrub to me. There are 3 flavors – Bubblegum (pink), Popcorn (yellow) and Mint (blue). It was a choice between Bubblegum and Popcorn, and....... Popcorn it was in the end! Bubblegum was nice, but it was just a one-dimensional kind of sweet.
Popcorn, on the other hand, is sweet and salty at the same time. I like that!
One thing I didn't quite fancy at the Lush store was the way customers were allowed to try the Lip Scrubs. When I asked if I could try the flavors, the store assistant simply told me to put my finger into the pot to get the bits.
You have to wet your lips and finger first so that the sandy bits would stay on your lips. That meant you either salivate your lips or wet it with water. The greater problem is that I'm sure 90% of people would just lick their finger at the store.
Double O.O"
Imagine how many thousands of salivated fingers have gone into those pots.
I walked to a basin and wet both my lips and finger, froze before the pots thinking about whether to dip my finger into the pots with lots of extra seasoning, and did it anyway. Lol.
A customer in the shop came up to me and asked if I'm Bun Bun too and told me she reads my blog. I felt so blessed that day!
Maybe you can try making your own lip scrub with the ingredients stated above. HOHO.
If you Google for it, there are plenty of home-made recipes for lip scrubs, lip exfoliators, lip moisturizers available. Most ingredients can be found in your kitchen too!
This is how it looks when in contact with water.
I think SGD20.00 for a lip scrub is pretty okie. And I do like the taste of it; I always feel happy after a scrub. And it's foolproof! Just gently rub the sandy bits on your lips and all your lip peels will be gone after a rinse.
I used it every day when I first had it, but the novelty wore off after a month or so and now I use it only occasionally. I think it's got to do with the fact that it's been really effective in exfoliating my lips so that it's no longer necessary to exfoliate them so often anymore. I don't even have to use lip balm! =D
When I know I'll be wearing a red lipstick, I'll definitely exfoliate my lips because no matter how expensive or luxuriously creamy/moisturizing your red lipstick is, nothing looks less sexy than red, chapped and peeling lips. So scrub away! 😀
Bun Bun rates Lush Lip Scrub in Popcorn:
Do you use lip scrubs? Have you tried making any yourself?


text:
Stories about lap dogs are everywhere, but researchers at the Virginia Tech College of Engineering can tell the story of dog lapping.
Using photography and laboratory simulations, researchers studied how dogs raise fluids into their mouths to drink. They discovered that sloppy-looking actions at the dog bowl are in fact high-speed, precisely timed movements that optimize a dogs' ability to acquire fluids. Their discovery appears today in the Proceedings of the National Academy of Sciences.
Researchers also compared what they learned about how dogs drink with what they knew from previous studies of cats. The scientists discovered that even though feline and canine mouths structurally are similar, their approaches to drinking are as different as — cats and dogs.
"We know cats and dogs are quite different in terms of behavior and character," said Sunghwan "Sunny" Jung, an associate professor of biomedical engineering and mechanics. "But before we did fundamental studies of how these animals drink fluids, our guess was dogs and cats drink about the same way. Instead we found out that dogs drink quite differently than cats."
Dogs and cats are biting animals and neither have full cheeks. But without cheeks, they can't create suction to drink — as people, horses, and elephants do. Instead they use their tongues to quickly raise water upward through a process involving inertia.
Both animals move their tongues too quickly to completely observe by the naked eye. But dogs accelerate their tongues at a much faster rate than cats, plunging them into the water and curling them downward toward their lower jaws, not their noses.
They quickly retract their tongues and a column of water forms and rises into their mouths, but they also curl the underside of their tongues to bring a tiny ladle of water upward.
Dogs precisely bite down to capture the water. In an instant they reopen their mouths and immerse their tongues back into the water.
Cats, on the other hand, lightly touch the surface of the water with their tongues, usually never fully immersing them, according to previous imaging by Jung and other researchers. When their tongues rise into their mouths, liquid adheres to the upper side, forming an elegant water column.
When dogs accelerate their tongues upwards, the latest research reveals a water column rising, but some water remains in the ladle of the tongue and is tossed to either side of the dog's mouth.
Although dogs do not use their tongues to actively scoop water into their mouths, it is possible that the scooped liquid has some positive effect on the water column dynamics below the tongue, the researchers said.
"Dog drinking is more acceleration driven using unsteady inertia to draw water upward in a column, where cats employ steady inertia," Jung said.
In all, 19 dogs of various sizes and breeds were volunteered for filming by their owners. Thirteen of the dogs were filmed outdoors at their owners' residences in the Blacksburg, Virginia, area. The remaining six were filmed at the Virginia Tech campus.
"This was a basic science study to answer a question very little was known about — what are the fundamental mechanics of how dogs drink?" said Sean Gart, a graduate student in biomedical engineering and mechanics who filmed the dogs. "Cats tend be viewed as neater, dogs are messier, but dogs really have to accelerate their tongues to exploit the fluid dynamics of the water column.
The researchers measured tongue motion, recorded water volumes, and generally measured lapping in the dogs. They used the results to generate a physical model in the laboratory of the tongue's interaction with the air-fluid interface, according to Jake Socha, an associate professor of biomedical engineering and mechanics at Virginia Tech.
Pavlos Vlachos, a professor of mechanical engineering at Purdue University, also participated in the study.The research, supported by the National Science Foundation, is an accomplishment of the Bio-Inspired Fluid Lab of the Virginia Tech College of Engineering. The lab seeks to take cues from living systems to make practical applications that exploit the natural movement of fluids.
http://www.sciencedaily.com/ Science Daily
http://www.sciencedaily.com/releases/2015/12/151214165730.htm Original web page at Science Daily


text: Purported CIA documents leaked Tuesday appear to confirm that the U.S. National Security Agency and one of CIA's own divisions were responsible for the malware tools and operations attributed to a group that security researchers have dubbed the Equation.The Equation's cyberespionage activities were documented in February 2015 by researchers from antivirus vendor Kaspersky Lab. It is widely considered to be the most advanced cyberespionage group in the world based on the sophistication of its tools and the length of its operations, some possibly dating as far back as 1996.From the start, the tools and techniques used by the Equation bore a striking similarity to those described in secret documents leaked in 2013 by former NSA contractor Edward Snowden. This relationship was further strengthened by the similarity between various code names found in the Equation malware and those in the NSA files.The new CIA documents leaked\u00a0by WikiLeaks include a 2015 discussion between members of the agency's Technical Advisory Council following Kaspersky's analysis of the Equation group.The discussion focused mostly on what the Equation did wrong that allowed Kaspersky's researchers to establish relationships between various tools and link them to the group. The goal was for the CIA's own cyber teams to learn from those mistakes and avoid them in their own tools and operations.The Equation's errors identified during the discussion included the use of custom cryptographic implementations instead of relying on standard libraries like OpenSSL or Microsoft's CryptoAPI, leaving identifying strings in the program database (PDB), the use of unique mutexes, and the reuse of exploits."The 'custom' crypto is more of NSA falling to its own internal policies\/standards which came about in response to prior problems," one team member said during the discussion. "In the past, there were crypto issues where people used 0 [initialization vectors] and other miss-configurations. As a result, the NSA crypto guys blessed one library as the correct implementation and everyone was told to use that.""The Equation Group as labeled in the report does not relate to a specific group but rather a collection of tools (mostly TAO some IOC)," another member wrote.TAO is a reference to the NSA's Office of Tailored Access Operations, a large division that specializes in the creation of hacking tools for infiltrating foreign computer systems. Meanwhile, IOC refers to the Information Operations Center, a CIA division that, according to a leaked 2013 budget justification for intelligence agencies, has shifted focus from counterterrorism to cyberespionage in recent years.The CIA analysis of Kaspersky's Equation report highlights how hackers can learn to better hide their attacks based on research published by security companies. This raises the question of whether security vendors and independent researchers should be so forthcoming with the methods they use to establish links between malware tools.\u201cIt is a proven fact that attackers learn from public analyses, and this is something that all researchers consider when publishing material," researchers from Kaspersky Lab said in an emailed statement. "It is a calculated risk. Of course, not all companies choose to disclose all their findings. Some companies prefer to keep some of the details for private reports, or not to create a report at all.""We believe that, going forward, a balance will be achieved between the amount of publicly disclosed information (just enough to highlight the risks and raise awareness) and the amount of information kept private (to allow for the discovery of future attacks)," the Kaspersky researchers said.According to them, this new information ties into the escalating cyber arms race that has been going on since 2012 and shows no signs of slowing down.Lead your comments over to Facebook.


text:
Joseph Biederman is a professor of psychiatry at Harvard Medical School. It makes a certain sense. According to Wikipedia, in 2007 he was
the second highest producer of high-impact papers in psychiatry overall throughout the world with 235 papers cited a total of 7048 times over the past 10 years as determined by the Institute for Scientific Information.
And he has won several awards:
Biederman was the recipient of the 1998 NAMI Exemplary Psychiatrist award. He was also selected by the Massachusetts Psychiatric Society Awards committee as the recipient of the 2007 Outstanding Psychiatrist Award for Research. In 2007, Biederman received the Excellence in Research Award from the New England Council of Child and Adolescent Psychiatry. He was also awarded the Mentorship Award from the Department of Psychiatry at the Massachusetts General Hospital.
But there's also this:
Biederman had pioneered the diagnosis of bipolar disorder in children and adolescents, a disorder previously thought to affect only adults. One of the world's most influential child psychiatrists, Biederman's work led to a 40-fold increase in pediatric bipolar disorder diagnoses and an accompanying expansion in the use of antipsychotic drugs – developed to treat schizophrenia and not originally approved for use in children – to treat the condition. However, Biederman and his colleagues Spencer and Wilens failed to accurately disclose the large consultancy fees they were receiving from pharmaceutical companies that make antipsychotics whilst conducting this research.
For which Biederman received a slap on the wrist from Harvard.
And there's this:
Dr. Biederman pushed [Johnson & Johnson] to finance a research center at Massachusetts General Hospital, in Boston, with a goal to "move forward the commercial goals of J.& J" [said Biederman in an email]
In other words, he felt no shame in admitting that he considered the commercial goals of Johnson & Johnson more important than the health of children with severe problems. One of the few people who can really help these children — by doing good research — he preferred to help Johnson & Johnson.


text:
Why Us?
We are very diligent about our protection of earth and its citizens. We hold the highest standards for our essential oil production process, bringing the world the finest products available. From the seed of the plant to the seal on the bottle, our high standards are integral with who we are.
A Higher Standard For Makeup
No synthetics, fillers, or additives. Try for yourself and discover the difference.
With a delicate consistency, this mineral formula is easily blended into your skin.
Lip Gloss
Made with 100% pure peppermint essential oil, make your lips look brighter and fuller with its high-gloss finish.
This mineral eyeshadow lasts all day to enhance your look, from natural to dramatic
Brighten your skin and enhance your natural radiance with this mineral powder.
Misting Spray
Make applying mineral makeup a breeze with this spray that contains rose, lavender, and other essential oils.
Highlight that natural radiance in your cheeks with our mineral blush formula.
Eyeshadow, eyebrow filler, and eyeliner in a single all-in-one powder.
Super lightweight lipstick that glides on effortlessly with medium coverage.
Finish that perfect look with this lustrous powder to last all day long.
Go from natural to bold with our powder formula eyeliner.
Rock That Look
Learn these tips and dazzle with your mineral makeup.
How To Choose Foundation Color
Get a cool or warm foundation to match. It's that easy!
Natural Remedies Guide
Looking for a natural alternative? We are so excited to share Health Canada approved
ways to use the following oils, approved as Natural Health Products (NHP)!
In addition to the topical and aromatic benefits of these oils, they can relieve symptoms
associated with common ailments, as well as restore, maintain,
and support good health.
See More Uses
Bruises, Burns, Cuts, and Minor Skin Issues
Bergamot Cedarwood Clary Sage Fennel German Chamomile Helichrysum Marjoram Myrrh Patchouli Rose Rosemary Frankincense Sage Thyme And More...
Cough or Cold
Angelica Basil Bergamot Black Pepper Cardamom Cedarwood Clary Sage Clove Cypress Eucalyptus Globulus Eucalyptus Radiata Fennel Geranium Ginger Helichrysum Lemon Jade Lemon Jasmine Laurus Nobilis Lavender Lime Marjoram Myrrh Myrtle Neroli Palmarosa Peppermint Pine Rose Rosemary Frankincense Sandalwood Sage Spearmint Tea Tree Thyme And More...
Digestive Health
Angelica Basil Bergamot Black Pepper Cardamom Citronella Clary Sage Digestive Support Digestive Enzymes Fennel German Chamomile Ginger Helichrysum Colon Support Lavender Lime Probiotics Marjoram Melissa Neroli Nutmeg Orange Patchouli Peppermint Rosemary Sandalwood Sage Spearmint And More...
Eczema and Dermatitis
Joint & Muscle
Angelica Black Pepper Cedarwood Celery Seed Citronella Clary Sage Clove Cypress Eucalyptus Globulus Eucalyptus Radiata Fennel German Chamomile Ginger Helichrysum Jasmine Laurus Nobilis Lavender Lime Lime Marjoram Nutmeg Peppermint Pine Rosemary Sage MSM Thyme Vetiver Wintergreen And More...
Farmessence NHP Collection
Enjoy natural relief from common ailments including cuts, bruises, burns, digestion, eczema,
dermatitis, cough and cold, headaches, stress, and joint and muscle pain with this
expansive collection of 15 natural health products (NHPs).
Includes 15 Health Canada-registered NHP oils and blends plus 10 bandages, custom carrying case, 1 oz hand sanitizer, and more.
Read More
See uses for more Natural Health Products approved by Health Canada!
See More Uses
Popular Product Categories
Your online health store
We are more than just the world's best essential oils. We go beyond green to help you create a healthy, healing home environment.
From effective, safe home cleaners to pet care, multivitamins to weight management, oral care to hair care, body care, and kids care, to wellness support and more, we offer solutions to help you live naturally.
Ordering online is fast and easy and the product ships right to your door. We are your online store for living a healthy, toxin-free lifestyle.Place an Order
Membership Benefits
- 24% off Retail Pricing
- No Minimum Monthly Order Required
- Easy Online Ordering, Shipped Right To Your Door
- Earn up to an additional 25% towards future purchases with our rewards program
Learn More


text:
Florida Gov. Rick Scott – and other top state officials – quickly distanced themselves last month from a controversial deal approved by Citizens Property Insurance Corp. to shift thousands of homeowner policies to a start-up insurance company.
But emails show that the Scott administration and other officials knew in advance about the unique deal that calls for Citizens, the state-backed insurance giant, to pay $52 million to Heritage Property Insurance and Casualty to absorb 60,000 policies.
Documents obtained by The Associated Press show that a lobbyist representing Heritage had met with a top Scott aide to discuss the transaction. The Scott administration acknowledged that the meeting happened in late March – roughly two months before the Citizens board approved the deal.
Scott's chief of staff Adam Hollingsworth insisted in a statement that no one in the Scott administration took a position before Citizens approved the transaction, known as a "take-out," on May 22.
"Our office does not weigh in for or against any Citizens take-out action. Instead, we expect the experts at Citizens and the Office of Insurance Regulation to act in the best interest of Citizens policyholders and the taxpayers that support the company," Hollingsworth stated.
Other state officials – including Chief Financial Officer Jeff Atwater – were also given information about the deal before the vote. Citizens officials sent an email to Atwater's personal email account the week before that included background material on the transaction.
Atwater, in the wake of news reports questioning the arrangement, talked to a top Citizens official hours before the transaction was approved. Atwater's spokeswoman said that Citizens had circulated a memo a few days before the vote but that Atwater "took no position, and did not encourage anyone at the Office of Insurance Regulation, Citizens' Board members or Chair, or Citizens' staff, to take a position on this transaction."
Citizens also sent material to House and Senate staff, although a Citizens spokesman said that emails to the House were apparently never received.
Citizens does not normally pay companies to absorb its policies although the board did approve a similar transaction earlier the year. Instead, Heritage is being paid to assume any claims associated with policies going back to January. But since Heritage gets to pick the policies it wants, the insurer could cherry-pick policyholders who have no claims pending.
Citizens officials have defended the deal as a way to shrink the size of the state-created insurer. Citizens currently has nearly 1.28 million policyholders. There has been a push to shrink the insurer because of fears that it would not be able to cover claims if a huge hurricane hits the state. Citizens has the power to place a surcharge, also called a "hurricane tax," on its own policies and policies of most insurance policies if it can't cover its losses.
But the backlash against the Heritage deal has already led legislative leaders to call for hearings in the fall to look into how the transaction was constructed.
Senate President Don Gaetz in a statement to senators said the "facts and circumstances surrounding the Heritage transaction need thorough investigation so the people of Florida are assured that it and transactions like it are in the best interest of Floridians."
Some have also questioned the deal because of campaign contributions.
Campaign finance records show that Heritage and affiliated companies have donated $176,000 in contributions since last year. Those donations include $110,000 to a political committee controlled by Scott and more than $40,000 to the Republican Party of Florida. Contributions to Scott's committee came in March.
Heritage representatives met twice with administration officials, according to a Scott spokeswoman. One of those was an introductory meeting in January. Fred Karlinsky, a Fort Lauderdale attorney and insurance lobbyist, met with Scott's deputy chief of staff Michael Sevi on March 27 to discuss the possible deal with Citizens.
Christine Turner Ashburn, the legislative affairs director for Citizens, noted the meeting in a May 17 email to top Citizens officials including CEO and President Barry Gilway. She said she was meeting with Sevi that morning to discuss the Heritage deal again.
"I intend to let him know that we believe we are on track to notice a board meeting for next Wednesday to take up the proposal as we understand the consent order has been or will be issued anytime," Turner Ashburn wrote.
Hollingsworth previously called it "outrageous" that anyone would suggest that the Scott administration influenced Citizens whose board members are appointed by Scott, Atwater and legislative leaders.
But Dan Gelber, a former state senator and leading Florida Democrat, said that "Scott's denials of influence peddling ring pretty hollow in light of these new emails."
Gelber said that Scott needs to return the $110,000 his political committee received "and answer some obvious questions as to why he took the money and what his office did or didn't do for the deal." Gelber's role in criticizing the deal has been called a partisan attack by the Republican Party since Gelber is close to former Gov. Charlie Crist, who may challenge Scott next year.
Heritage officials, meanwhile, have already begun defending themselves to state leaders.
Bruce Lucas, chairman of Heritage, sent a letter May 31 to Gaetz that his company has been the victim of sensationalized media coverage.
He contends that the final amount Heritage will get out of the transaction may not be $52 million because some Citizens customers may decline coverage. He also disputed the notion that his company will be able to "cherry pick" policies that do not have any claims because some homeowners may not have yet filed claims for this year. Tropical Storm Andrea, for example, brought heavy rains to the state earlier this month.
Was this article valuable?
Here are more articles you may enjoy.


text:
5 copy price $11.17
10 copy price $10.39
Loyalty Points
Loyalty Points
Fun, interactive Bible devotions for the whole family to enjoy!
Devotional Dippers are a great way to get your whole family to open up the Bible together. Each stick includes a theme, a Bible reference for you to read, a question to discuss, and a prayer point to encourage you to speak to God. It can be easily adapted to suit children of different ages. Each tube includes a detailed instruction leaflet.
No reviews have been added for this product.
Total Price: $1.99


text:
28-year-old Sherwin Shayegan, who has been dubbed the "Piggyback Bandit" by authorities, was finally arrested in Montana due to his history of "jumping on the backs of high school athletes in Oregon and Washington state."
This means that Shayegan —which sounds a bit like 'shenanigan'. coincidence?— has been going from state to state doing his own sort of semi-national tour of unwanted piggyback rides. Classy.
Helena Police Chief Troy McGee says police received a tip that 28-year-old Sherwin Shayegan was at a high school boys soccer tournament in Helena on Friday and observed him jump on a player's back.
Apparently, officials had been warning athletes about Shayegan's love of surprise activities that almost no one does past the age of eight and is pretty much the last thing you'd think would happen without your consent, but that didn't stop it from happening again.
Last spring the Oregon School Activities Association warned athletes to look out for Shayegan after officials say he turned up at events in Eugene and Pendleton and got piggyback rides from some athletes.
Police in Bonney Lake, Wash., say Shayegan gave a high school athlete money and jumped on his back.
At least he paid them? Or is it worse because he paid them? I don't know. I'm still trying to understand how this is a for-real story and what might've happened to Shayegan to cause his descent into piggyback madness.
'Piggyback Bandit' arrested in Mont. after police say he jumped on high school athletes' backs [Washington Post]


text:
Proactive Support Services
We Build Great Partnerships & Long Lasting IT Infrastructure
We understand why your critical business services are so important to your daily operations. This is why we spend so much time aligning our technology to support your initiatives. We build a program that relies on 24x7x365 network monitoring coupled with an aggressive preventative maintenance program which ensures optimum uptime for your business.
Our Down to Business Services Solution
One of the major challenges in maintaining a computer network is trying to predict what will fail and when. With our Down to Business Services solution, we can prevent many network failures from ever happening. By combining regular and comprehensive preventative maintenance and robust real-time monitoring of your critical network and desktop devices, we ensure the reliability and stability of your IT assets. This solution is so effective that our customers see almost immediate results. A regularly maintained network means fewer failures, yielding higher productivity and savings on support costs for you. At the same time, your exposure to security risks is dramatically lessened, and frustration from unstable IT resources almost vanishes. We allow our customers to focus on their core business functions by taking the worry out of owning a computer network.


text:
When we first came up with the idea for Postepic app we had bookworms like ourselves in mind. It was about capturing little gems we found in books we were reading and were not able to share with each other.
So the brand is all about the quotes and promoting books. The logo is composed of two quotation marks superimposed on each other using negative space in a way that they form a composition that looks both like a growing wave and a variation of a comic bubble.
Read more about the Postepic mobile app
Postepic brand used in Press Kit design
Postepic website design
Third Rail
Third Rail Graphics is a boutique creative agency domiciled in Dubai, United Arab Emirates. We operate as a network of highly skilled and experienced creatives from Europe and the Middle East that mobilize on a project basis. We are graphic designers, illustrators, social media experts, developers and product managers.About the Third Rail Graphics
Brand development
Video content
Design for print
Brochures, flyers, infographics, corporate documents, presentations, placemats... We take great pleasure in expanding on company's branding and designing great layouts for print.Learn more about our services
Webdesign portfolio
Webdesign is a beautiful art of combining creative design with functionality and efficiency. It creates an ultimate platform for the brand to flourish.Learn more about webdesign services
Postepic is a book quotes sharing and discovery mobile app developed and launched by Third Rail.Learn more about the app
Video Clips
Short video clips are one of the most captivating means of communications used on social media and during the events these days.Learn more about our services
Developing a brand is probably one of the most exciting of all creative tasks. It starts with long discussions and ends with carefully crafted concept setting the stage for company's communications.Learn more about our services
Third Rail's Portfolio
Here you can see examples of our design work spanning from being philosophical about the brand, through thought bending layouts, to crafting perfect website icons.Learn more about our services
Web and email design
Design for Print
Marketing managers often find themselves between the rock and a hard place.
Their budgets do not allow them to use services of big international agencies, and at the same time, they are often short on resources that could provide them with essential marketing aspects such as creative graphic design, digital online presence, events or integrated marketing communications.See what Third Rail Graphics can do for you
Got a Question?
We are here for all your graphic design, web development and communications needs. If you want to learn more about us and how we can help you, send us a quick note.Contact Us
Check this out!
Karolina Burdon
Meet the Founder
Maciej Napierala
Charity Fundraising
Say Hi!
- Third Rail Marketing Consulting FZE LLC
Level 14, Boulevard Plaza Tower 1
Dubai, United Arab Emirates
- +48 732530987
- firstname.lastname@example.com
- LinkedIn Profile


text: hi there. i am running debian's stable codenamed Sarge. i followed the tutorial from http://www.howtoforge.com/forums/showthread.php?t=21 about installing a new kernel. after that when i boot the system to the new kernel all i get is: VFS: cannot open root device "hda5" or unknown-block (0,0) please append a correct "root=" boot option kernel panic - not syncing : VFS :unable to mount root fs on unknown -block(0,0)


text:
Our spare parts
How do I place an order?
1. Select your product
Select the product you would like to order.
2. Add product to your shopping cart
Add the product you would like to buy to your shopping cart. You can add more then one product. When you are ready with your shopping you can proceed to checkout.
3. Fill in your information
Fill in your information.
4. Fill in your shipping address
If you would like us to ship your order to a different shipping address, you can fill this in.
5. Pay for your order
Pay your order by bank transfer or Paypal.
6. Receive your order
After receiving your order and payment we will ship your order as soon as we can. You will receive an e-mail from the shipping company the evening the order is shipped.


text:
Two months after critical vulnerabilities were patched in Apache Struts, a popular open-source framework for developing Java-based Web applications, VMware released a security update to incorporate the fixes in its vCenter Operations Management Suite product.
The vCenter Operations Management Suite can be used to monitor and manage the performance, capacity and configuration of virtualized infrastructure. It depends on Struts for some of its features.
"The Apache Struts library is updated to version 126.96.36.199 to address multiple security issues," VMware said in a security advisory Tuesday that coincided with the release of vCenter Operations Management Suite (vCOps) version 5.8.2.
Apache Struts 22.214.171.124 was an emergency update released on April 24 after it was revealed that a fix included in Struts 22.214.171.124 for a remote code execution vulnerability was insufficient and could be bypassed.
The bypass was treated as a separate vulnerability and was assigned the CVE-2014-0112 tracking number, superseding the original issue known as CVE-2014-0094.
The vCOps 5.8.2 also incorporated a patch for a denial-of-service vulnerability tracked as CVE-2014-0050 that was also originally patched in Struts 126.96.36.199.
"VCOps is affected by both CVE-2014-0112 and CVE-2014-0050," VMware said in its advisory. "Exploitation of CVE-2014-0112 may lead to remote code execution without authentication."
Users of the older vCOps 5.7.x branch are advised to either upgrade to vCOps 5.8.2 or to manually apply a workaround described in a separate knowledge base article.
Another VMware product called vCenter Orchestrator (vCO) is affected only by the denial-of-service issue (CVE-2014-0050), but no patch has been released yet.
This story has been corrected at 5:14 PM on June 27. A previous version of the story incorrectly suggested that a VMware product was affected by a vulnerability identified as CVE-2014-0116. The product is not affected by that vulnerability.


text:
Wednesday, February 27, 2008
Picture of the Day - The Airliner Chronicles
7 comments:
- Callan Bentley said...
Looks to me like there's an initial left-right extension, which has opened up a series of top-bottom-trending fractures. I can't quite tell, but it looks like the left half is lower-elevation than the right half of the photo, and transverse fractures open up on glaciers as they descend (perhaps from the ice sheet down into one of the valley glaciers leading to the ocean?). My interpretation continues that an overlying layer of snow has sagged down into the crevasses, more in some areas, less in others (so the crevasses' surface expression appears as a "dotted line"). Finally, wind has come along and exploited this topography, and piled up ridges of snow leading from the distant edge of each sag-hole off to the upper-left. Just a guess, but that's my instinct looking at the photo.
- February 28, 2008 at 3:58 AM
- Ron Schott said...
- February 28, 2008 at 4:05 AM
- Silver Fox said...
I'd just like to say, Wow - to the picture, not to the extensive analysis. I find everything about snow and ice fascinating, and this is an exceptional air-flight photo.
- February 28, 2008 at 5:13 AM
- Silver Fox said...
Well, maybe that would be "extensional" ?
- February 28, 2008 at 5:14 AM
- Mel said...
I'll third Callan's response. I was going to reply with a simple crevasses explaination, but Callan has done a wonderful job. I'll add that the smaller patch of crevasses about 2/3 up the photo appear to be coming from a glacier at the top of the photo and are "falling" over the rock ledge visible in the photo.
- February 28, 2008 at 11:54 AM
- Garry Hayes said...
Thanks for all the comments! This wasn't a quiz where I knew all the answers this time around; I found the feature kind of mysterious as well. Callan is most certainly correct, in that there are clearly crevasses caused by the west to east flow down some kind of declivity, and clearly wind has caused snow to pile up in ridges transverse to the direction of the crevasses. I found myself wondering: did the crevasses collapse, forming icy grabens, or has the blowing snow filled the crevasses, but not completely? I noticed the presence of gaps and holes just to the right where clearly more crevasses are hidden by a smooth surface of snow and ice.
I shiver just thinking about ambient conditions on the ground where the wind blows this much...
- February 28, 2008 at 4:45 PM
- Geology Happens said...
...and I thought it was a ski area after hours and before it was groomed.
- February 28, 2008 at 8:10 PM


text:
You may also like
Shop our latest pillow arrivals!
Shop our latest pillow arrivals!
Are you a designer? Sign up to our trade program for exclusive discounts and offers!
Are you a designer? Sign up to our trade program for exclusive discounts and offers!
The Skye Collection is timeless and classic with a beautiful, old-world design in a variety of colour choices. Power-loomed in China of 100% polyester, these printed designs provide the textured effect of high-end rugs at an affordable price.
Shop the Skye Collection here.
Fabrication: Power Loomed
Materials: 100% Polyester Face
Origin: China
Pile Height: 0.13"
Backing: Canvas
Rug sizes are rounded to the nearest foot. Exact dimensions are below:
2'3" x 3'9"
2'6" x 7'6"
3'6" x 5'6"
5'0" x 7'6"
7'6" x 9'6"
9'0" x 12'0"
Clean spills immediately by blotting with a clean, dry sponge or cloth. Appropriate rug pad is highly recommended on all surfaces to prevent slipping, add cushion, and improve durability. For vacuuming, use a vacuum cleaner without a beater bar or one where you can set the bar to the highest pile setting. If your vacuum has variable power settings, set on low. Vacuum full length of the rug, turn and repeat to the next area, rather than back and forth motion.
All rug care instructions can be found here.
We custom curate all of the products on our site from an array of sources around the globe. We are intentional with our selection process and look for well-designed and carefully crafted pieces that pay homage to our "Warm Modern" signature style. As such, we genuinely hope you love our pieces as much as we do but, should you be unhappy with your purchase in any way, please review the details below.
We do have limitations on returns for cost, space and sustainability reasons! We encourage you to read our product descriptions thoroughly, triple measure your space, and reach out to us with any questions to firstname.lastname@example.com prior to making your purchase! This way we can help ensure you have all the information you need to make your purchase.
For specific details on returns, please check out our full Return Policy.
Subscribe to receive updates, decor inspiration, tips & tricks, exclusive deals, and more!


text:
Introducing Real-time Segments for Android and iPhone. (*See below for a quick refresher on Strava segments.) Want to know exactly how you performed immediately after completing a segment? Want to see how you stack up against friends who ran or rode the same segment moments before you? One of the most requested features by Strava athletes has arrived.
Instant Segment Times Right to Your Phone
Real-time Segments gives Premium members their segment times instantly and removes the wait — see the day's leaderboard and where you stand immediately after completing the segment. Settle any debates with friends about your times while you catch your breath at the end of a big push.
Track Your Friends and Go Hands Free on Android
Now available on Android and coming soon to iPhone, see which of your followers on Strava are currently out riding or running. Go join them, or get that extra motivation to post a time next to theirs on that day's segment leaderboard. Premium members can opt-in to this feature (note that it is "off" by default) and choose to share their Active status as well as real-time segment stats with followers.
Real-time Segments for Android, and coming soon to iPhone, will also have audio support on popular segments so you can listen to your segment times after a segment effort.
Turn on Real-time Segments and Active Friends
Enable Real-time Segments by swiping left to the Segments screen and tapping Real-time Segments and Active Friends, or by tapping on the gps location icon on the Record screen. iPhone users can tap the segment location icon on the Record screen to turn the feature on or off. Please note, Real-time Segments will use more battery and data in order to update your results immediately.
Check out this quick video to see Real-time Segments and Active Friends in action. Go Premium for only $6 per month or $59 per year and change the way you train.
*What's a Segment?
As a refresher, a segment is our term for a specific section of road or trail (learn how you can create a segment of your own in your area). Almost every segment on Strava has a leaderboard so you can track your progress on a given segment, and see where you stack up against friends and locals who have ridden or run the same segment.


text:
By David Crane defrev (at) gmail (dot) com September 21, 2009 Updated May 31, 2010 Back in June, DefenseReview published an article on the Ruger SR-556 piston AR. Well, it's now official: Everyone AND their mother is now making short-stroke gas piston/op-rod AR (AR-15) carbines and SBRs (Short Barreled Rifles). SIG SAUER has just entered the game with their SIG516 …Read More »
Tag Archives: ruger sr-556 piston
Ruger SR-556 Gas Piston/Op-Rod AR Carbine User Feedback: Case Extraction Problem and Solution.
By David Crane defrev (at) gmail (dot) com August 26, 2009 Back on June 7, 2009, DefenseReview published a heads-up piece on the new Ruger SR-556 gas piston/op-rod AR-15 tactical carbine. In that piece I wrote this: "One of the things were going to investigate is whether or not the SR556 is completely debugged, or whether it has the normal/usual …Read More »